Member access

4-Traders Homepage  >  Shares  >  Amex  >  CEL-SCI Corporation       US1508374097

 SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
Company
CEL-SCI Corp. is a biotechnology company, which is involved in the research and development of investigational immunotherapy products for the treatment of cancer and infectious diseases.The company's lead investigational therapy, Multikine, is being developed as a potential therapeutic agent... 
More about the company
Financials ($)
Sales 2014 0,25 M
EBIT 2014 -24,8 M
Net income 2014 -22,9 M
Debt 2014 -
Yield 2014 -
Sales 2015 0,26 M
EBIT 2015 -26,9 M
Net income 2015 -27,0 M
Debt 2015 -
Yield 2015 -
PER 2014 -
PER 2015
Capi. / Sales 2014 296x
Capi. / Sales 2015 279x
Capitalization 72,6 M
More Financials
Latest news on CEL-SCI CORPORATION
2d ago CEL SCI : NEW STORY CEL-SCI & U.S. Navy Administer Multikine to First Volunteer ..
2d ago CEL SCI : & U.S. Navy Administer Multikine to First Volunteer Patient in Phase I..
6d ago CEL SCI : University of Minnesota's Masonic Cancer Center Added to Phase III Hea..
7d ago WEDNESDAY SECTOR LEADERS : Drugs, Biotechnology Stocks
09/18 ERGOMED : Provides Update on Co-Development Partnerships
09/16 CEL SCI : University of Minnesota's Masonic Cancer Center to Join Phase III Head..
09/11 CEL-SCI CORPORATION : Valuation Analysis for CEL-SCI
09/11 CEL SCI : Valuation Analysis for CEL-SCI
09/10 CEL SCI : NEW STORY University of Minnesota Masonic Cancer Center Joins CEL-SCI'..
09/10 CEL SCI : University of Minnesota Masonic Cancer Center Joins CEL-SCI’s Ph..
09/03 CEL SCI : NEW STORY CEL-SCI Enrolls 20 Patients in August in Its Phase III Immun..
09/03 CEL SCI : Enrolls 20 Patients in August in Its Phase III Immunotherapy Head and ..
More news
Comments 
Advertisement
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF